Asston Pharmaceuticals Limited concluded its seventh Annual General Meeting (AGM) on September 29, 2026, approving critical corporate resolutions including the appointment of statutory auditors and revisions to director remuneration.

The meeting, conducted via Video Conferencing/Other Audio Visual Means, saw shareholders vote on six agenda items. Key approvals included the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the reappointment of Mr. Ashish Narayan Sakalkar as Managing Director. The board also approved an increase in remuneration for the Managing Director, Whole Time Director and CEO Mrs. Saili Jayaram More, and Non-Executive Director Mr. Sachin Chandrakant Badakh.

Resolutions Passed at the AGM

Shareholders voted on both ordinary and special resolutions through remote e-voting and instant voting during the meeting. The following table summarizes the key agenda items put to vote:

Meeting Proceedings and Attendance

The meeting commenced at 12:30 pm with a quorum present. Mr. Rishi Upadhaya, Company Secretary and Compliance Officer, welcomed attendees and briefed them on the virtual participation guidelines issued by the Ministry of Corporate Affairs and SEBI. Mr. Ashish Narayan Sakalkar chaired the proceedings.

The Company Secretary noted that no shareholder emails were received requesting registration as speakers for the meeting. Any prior questions submitted by shareholders had already been addressed via email to their registered addresses.

Voting Mechanism and Scrutiny

Remote e-voting was available from September 26, 2026, at 9:00 am until September 28, 2026, at 5:00 pm. Members who did not vote remotely could cast their votes instantly during the AGM via the NSDL platform. Ms. Pragya Jain, a Practicing Company Secretary, served as the Scrutinizer to ensure fair and transparent vote counting.

The combined voting results, along with the Scrutinizer's report, are scheduled to be declared within two working days of the meeting's conclusion. These results will be published on the company's website and communicated to BSE Limited in compliance with Listing Regulations.

Asston Pharmaceuticals has scheduled its seventh annual general meeting for September 29, 2026. The meeting will address key governance matters, including the re-appointment of the managing director and significant remuneration increases for senior leadership.

The company’s board of directors met on September 4, 2026 to approve these changes. The AGM will be conducted via Video Conferencing and Other Audio Visual Means. M/s Pragya & Associates has been appointed as the scrutinizer for the meeting.

Remuneration Increases

The board proposed special resolutions to increase the monthly remuneration for three key executives, effective from October 1, 2026 through September 30, 2029. These increases require shareholder approval at the AGM.

Mr. Sakalkar, who is retiring by rotation, is also seeking re-appointment as Managing Director. The resolutions note that these payments will continue even if the company reports no profits or inadequate profits during the tenure, subject to statutory approvals under Schedule V of the Companies Act, 2013.

Auditor Appointment

The company appointed M/s Panchal S K & Associates as its statutory auditor for a term of five years, commencing from the conclusion of the current AGM until the conclusion of the 12th AGM. The proposed fees are ₹5,00,000 excluding taxes and out-of-pocket expenses. M/s Yash A. Jain & Associates was appointed as internal auditor.

Financial Performance Context

The explanatory statement accompanying the notice highlights the company’s financial performance for FY26. Gross turnover stood at ₹3158.43 lakh, with profit before interest, depreciation and tax (PBIT) at ₹555.01 lakh. Net profit for the period was ₹386.52 lakh.

AGM Logistics

The cut-off date for determining eligible shareholders for e-voting is September 22, 2026. Remote e-voting will be facilitated by National Securities Depository Limited (NSDL), beginning on September 26, 2026 and ending on September 28, 2026.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0SJX01015/dab3a30d-ecba-411f-a722-4a951933ab07.pdf